The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); Bellicum Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); Hutchison MediPharma (Inst); IGM (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Novocure (Inst); Numab (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Treadwell Therapeutics (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical
 
Kian-Huat Lim
Research Funding - Aclaris Therapeutics
 
Mark E. Burkard
Consulting or Advisory Role - Novartis; Pointcare genomics; Strata Oncology
Research Funding - Abbvie (Inst); Apollomics (Inst); Apollomics (Inst); Arcus Ventures (Inst); Loxo (Inst); Merck (Inst); Puma Biotechnology (Inst); Strata Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent for a method to detect recombination events with CRISPR-mediated editing.; I have patent for implantable/localized drug delivery device that can sample the tumor microenvironment and deliver drug.
 
Samuel J Klempner
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - Natera
Consulting or Advisory Role - Astellas Pharma; Boston Biomedical; Bristol-Myers Squibb; Foundation Medicine; Lilly; Merck; Pieris Pharmaceuticals
Speakers' Bureau - Foundation Medicine
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst)
Other Relationship - NCCN
 
Mark A. Socinski
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Genentech; Guardant Health; Lilly; Merck; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune; Genentech; Janssen; Lilly; Novartis
Speakers' Bureau - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Genentech (Inst); Spectrum Pharmaceuticals (Inst)
 
Shirish M. Gadgeel
Honoraria - AstraZeneca; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Jazz Pharmaceuticals; Novartis; Novocure; Takeda; Xcovery
Research Funding - Aeglea Biotherapeutics (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Lycera (Inst); Merck; Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck
Other Relationship - AstraZeneca
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Calithera Biosciences; Euclises; Exelixis; Genentech; Guardant Health; Loxo; Precision Health Economics; Seagen; Takeda; Tesaro
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ARIAD (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Loxo (Inst); Molecular Partners (Inst); Pfizer (Inst); Seagen (Inst); Xcovery (Inst); Zeno Pharmaceuticals (Inst)
 
Shawn Michael Leland
Employment - Elevation Oncology
Leadership - Elevation Oncology
Stock and Other Ownership Interests - Elevation Oncology; Verastem
Patents, Royalties, Other Intellectual Property - Elevation Oncology, Inc. patent listed as an inventor - US 62/948,565; Verastem, Inc patent listed as an inventor - US 62/739,658
Travel, Accommodations, Expenses - Elevation Oncology; Verastem
 
Doug Plessinger
Employment - Elevation Oncology; Global Biotechnology & Cancer Therapeutics
 
Lori A. Kunkel
Stock and Other Ownership Interests - Atreca; Curis; harpoon therapeutics; Nurix; ORIC Pharmaceuticals
Consulting or Advisory Role - Principa Biopharma; Takeda
 
Efrat Dotan
Honoraria - Boston Biomedical; Pfizer
Consulting or Advisory Role - ARMO BioSciences
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst)
 
Gregory Alan Otterson
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Guardant Health; Novocure; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - Turning Point Therapeutics
Honoraria - ARIAD/Takeda; AstraZeneca; Foundation Medicine; Genentech/Roche; Merck; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche/Genentech; Takeda; TP Therapeutics
Speakers' Bureau - AstraZeneca; Genentech; Takeda
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Ignyta (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Tejas Patil
Stock and Other Ownership Interests - crispr therapeutics; Guardant Health; Novartis; Roche/Genentech
Honoraria - Aptitude Health; Physicans' Education Resource; Roche/Genentech
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Lilly; Sanofi/Aventis; Spectrum Pharmaceuticals; Syntha Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bayer; GlaxoSmithKline; Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Edward S. Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Merck; Pfizer; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Pfizer; Roche/Genentech; Takeda
Research Funding - Boehringer Ingelheim; Genentech/Roche; Ignyta; Merck
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Merck; Pfizer; Takeda